AAV-ligand Conjugates, a New Capsid Platform For Improved Gene Therapy Delivery

Time: 11:30 am
day: Track A - Day 1 AM


  • AAV capsids from 1st and last generations limitations (efficiency and safety) are related to the nature of the capsid composition
  • Chemical conjugation of AAV capsid alter dramatically the biology of AAV leading to improve bio distribution, transduction and immunological profile
  • Chemical conjugation of AAV is a versatile and scalable new capsid technology